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Dallas, Texas
Implantable cardiovener-defibrillators have become an ac-
ceptable mode of therapy tbr survivors of cardiac arrest,
They are also indicated in patients with recurrent sustained
ventricular tachycardia rtsistnnt to anriarrhythmic drugs
and, en occasion, in patients with recurrent syeccpe but nn
documented arrhythmias who have sustained ventricular
tachycardia initiated by programmed ventricular stimula-
tion . In addition, there is a growing trend toward use of the
implantable cardioverter .dcflbrillator in patients with heart
disease, especially those with recent myocardial infarction,
who have multiple risk factors for sudden cardiac death
associated with inducible sustained monomorphic ventricu-
lar lachycardia unresponsive to antiarrhythmic drugs . If
such treatment becomes commonplace, there will he a major
expansion of the already vigorous industry developing,
manufacturing and applying these devices, with enormous
implications for screening, investigation and triage of pa-
dents and, consequently, for the cost of health care delivery
in this nation.
The Resent study. In this issue of the Journal, Fogaros e i.
al . (I) present an important retrospective analysis o€ 217
patients who survived cardiac arrest and whose subsequent
therapy was based oil electrophysiologic testing. Among
these patients, inducible ventricular tachycardia was not
present in approximately 40%, responded to drug therapy
during serial electrophysiologic testing in approximately
20%a and did not respond to drug therapy during testing in
approximately 40% . Of the 81 patients without inducible
arrhythmia who were not treated with antiarrhythmic drugs .
23 were treated with an implantable cnrdiovener-defihrilla-
tor . The 51 patients whose arrhythmia responded to anti .
arrhythmic drugs in the electrophysiology laboratory were
treated with the successful drug . Of the 85 patients with
unsuccessful drug testing, 47 received an implantable car-
diovcrter-defibrillator and 38 were given amiodarone or
other drugs .
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The study confirmed what has become apparent is recent
retrospective studies . namely, that the incidence of sudden
death and overall mortality is similarly high across all
subgroups
. The 2-year mortality rate for sudden cardiac
death was 8 t
3%, 6 ± 3% and 8
t
3% in the three groups,
respectively
. The total 2-year mortality rate was 22 ± 5%, 24
s 13 and 17 t 4%
. respectively . On the other hand, as
expected, recurrent arrhythmic events were more common
in the nonresponders (35 ± 5%) than in responders (13 t 5%)
or patients with no inducible arrhythmia (19
T
5%) after 2
years . Patients were treated with the implantable cardio-
verter-dehhrillatcr on the basis of the investigators' clinical
judgment, and the device was implanted in 29% of patumts
with no inducible arrhythmia, 2% of patients with successful
and 55% of patients with unsuccessful drug testing . Only 2 of
the 71 recipients of art implantable cardiovener-defibrillator
experienced sudden death . The actuarial incidence of sud-
den death was I ± I% at 2 years and the overall actuarial
mortality rate was b ! 3% at 2 years for recipients of an
implantable cardiovener-defibriltator
. These data are re-
markably close to those previously published from the data
base of Cardiac Pacemakers (2) and by Winkle ci al . (3) .
Strengths and hntitetivus of rice study . Overall, this retro-
spective study is useful in confirming the data from previous
retrospective studies and in demonstrating trends that can be
subjected to future prospective analysis Our strength of the
study i
:s that it reflects the actual practice of conscientious
electrophysiologists managing a diverse pool of patients whe
were resuscitated from cardiac arrest . These patients were
managed with all the uncertainties of clinical practice and the
difficulties ofdecision makingin a complex group . There are
some inherent weaknesses in the study that do not detract
from the importance of the overall message . The study
patients were an inhornngeneous group in that l5% had
cardiemyopathy, 12% bad valvular heart disease and 9% had
no definable heart disease in addition to the 7C% with
coronary artery disease . A further inhomogeneity is intro-
dosed in that the "baseline" electrophysiologic study was
necessarily performed during amiodarone therapy in seven
patients
. It is difficult to know how this factor might have
influenced the initial ctassificatioa of patients based on rite
inducibility of arrhythmia at electrophyoiologic study. Pa-
tients with inducible nonsustained ventriculartachycareiaer
inducible polymorphic ventricular lachycardia were treated
in much the same way as those with inducible sustained
monomarphic ventricular tachycardia . These days, most
eleclrephysiologsts would find such a baseline result from
programmed stimulation a difficult one from the point of
view of defining efficacy of antiarrhythmic drugs and would
usually classify such patients with those with no inducible
ventricular arrhythmia from the prognostic standpoint.
DeSuing th causes of death . As with many studies of this
type, a rather old-fashioned separation of causes of death is
utilized . Fad points in arrhythmia smiles have always been
the most hotly debated and must difficult issue for study
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designers . A sudden witnessed death is usually a clear end
point
. Unwicnessed deaths within I h of the onset of one or
more cardiovascular symptoms and death during sleep arc
end points that may somewhat cloud the issue because these
may not be clearly "instantaneous" deaths. The designation
"nonsudden cardiac death" to include all other cardiovas-
calar deaths potentially greatly obscures the possible impact
of arrhythmia recurrences an death
. In this regard, a helpful
recent article by Kim et a] . (4), is noted. In this article the
authors correctly highlight the problem ofarrhythmia which,
though not immediately fatal, may lead within a few hours or
days to death, emphasizing the biologic impact of arrhythmia
recurrence . This concept of "not so sudden death" has
much to recommend it and designers of future prospective
trials would do well to attempt to include such a c!assifica-
lion . To detect such "not so sudden deaths" would require
careful arrhythmia monitoring. Third and fourth generation
implantable cardioverter-defibrillators capable of extensive
telemetry, including in some cases actual etectrograms dur-
ing arrhythmic events, should facilitate a precise definition
of cause of death in such patients.
Implications. On the basis of theirexperience, Fogoros et
at. (1), have identified several areas for useful study in town
prospective trials . These include I) Which high risk patients
from among the various subgroups stand to derive the
highest benefit from the implantable cardioverter-defibrilla-
lar? 2) What is the optimal use of the implantable cardio-
verter-defibrillator in patients who have no inducible ven-
tricular arrhythmia after resuscitation from sudden death?
3) Does the implantable cardioverter-defibrillator have a role
even in patients who respond to drug therapy? It is do
interesting idea that these patients, who have a relatively
good prognosis because of well preserved left ventricular
function . may live long enough to benefit from implantable
cardioverter-defibrillator implantation even though the nu-
meric risk of arrhythmia recurrence is relatively low,
4) What is the value of empiric drug therapy in patients
without inducible ventricular arrhythmias or with only in-
ducible ennsuatained arrhythmias with the protection of an
implanted implantable cardioverter-defibrillator^
These questions and others will probably he addressed in
several ongoing prospective studies recently initiated . The
Coronary Artery Bypass Graft/Patch Study (CABG Patch)
will determine the effect of the implantable cardiuverler-
defibrillaror on mortality and arrhythmia occurrence in pa-
tients with left ventricular dysfunction but
no previous
episode of cardiac arrest or ventricular tachycardia under
going coronary artery bypass grafting . The Multi-center
Automatic Defibrillator Implantation Trial (MADIT) will
examine survival of high risk patients with coronary artery
disease and left ventricular dysfunction, but without a prior
cardiac arrest, randomized to implantable cardiovener-
defibrillator implantation or conventional drug therapy . The
Mufti-center Unsustained Tachycardia Trial (MUSTT) will
examine the impact of implantable cardioverter-defibrillator
therapy with that
of drug therapy guided by electrophysio-
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logic testing in patients with coronary artery disease, left
ventricular dysfunction and spontaneous unsustained ven-
tricular tachycardia . The Sudden Death Prevention Study
(SDPS) will examine end points similar to those of the
MCSTT trial . In Europe, the Dilated Cardiomyopathy
(DCMI trial will determine the efficacy of implantable car-
dioverter-defibrillator therapy in improving prognosis in
patients with congestive cardinmyapathy and law ejection
fraction but with no previous episode of cardiac arrest or
sustained ventricular tachycardia
. A cost-effectiveness
study is also being initiated in Europe to determine if
implantable cardioverter-defibrllator therapy, when used as
the therapy or first choice in patients who have survived a
cardiac arrest after myocardial infarction, is both efficacious
and cost-effective .
Future challenges. We are already experiencing a rapid
expansion in technology and application of this sophisticated
mode of therapy to larger groups of patients worldwide. The
intricate complexity of third and fourth generation implant.
able cardioverter-defibrillators capable of sophisticated pro-
grammed stimulation, programmable shocks, bradycordia
pacing, telemetry and Hotter-type monitoring provides many
challenges to the electrophysiologist, the implanting physi-
cian and the follow-up team in tailoring therapy to the
individual patient
. It is not at all clear that the specific needs
of a patient can be understood at the time of implantation
because they may change with time and the impact of
advancing myocardial disease, variations in drug therapy
and fluctuations in electrolyte balance . The complexity of
modern implantable cardioverter-defibrillators has intro-
duced new potential for error by the programming physician
and increased the challenge to engineers and physicians to
ensure that these devices become safer as well as more
effective. The prototype implantable cardioverter-defibrilla-
tor, the automatic implantable defibrillator, simply gave a
shod, which is still all that many patients need . Protracted
attempts to terminate ventricular rachycardia by pacing may
result in an inexorable ischemic episode, rendering the
arrhythmia more resistant to electrical therapy
. The device
industry needs to recognize this problem very clearly
. Pro-
viding patients with an optional warning signal to alert them
to the initiation of pacing therapy for arrhythmias that may
not immediately cause catastrophic symptoms would be
advantageous
. This option would allow the patient to stop
the activity that may have precipitated the arrhythmia,
initiate traustelephonic telemetry or alert a family member or
colleague to the presence of arrhythmia ; in this way appro-
priate emergency care can be mobilized, if necessary, and
potential device-related mortality may be averted . During
this decade of continuing exploration and research it will
become increasingly important to examine whether implant-
able cardioverter-defibrillator therapy should become gener-
ally available to cardiologists with minimal training in elec-
trophysielegy or whether it should remain the function of
experts within specialized centers of excellence .
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